Annual Report Reveals Substantial Doubt About Going Concern, Mounting Losses, and Highly Dilutive Financing
BDPT sits 15% above its 52-week low of $0.01 on elevated volume (2.2× avg).
Summary
BioAdaptives, Inc.'s 2025 annual report reveals critical financial instability, including a going concern warning, increased losses, negative working capital, and reliance on highly dilutive financing, compounded by significant governance deficiencies.
Key Events · Corporate Governance and Compliance · BDPT
-
Substantial Doubt About Going Concern
Both management and the independent auditor explicitly state substantial doubt about the company's ability to continue as a going concern due to accumulated deficits and ongoing capital requirements.
-
Significant Financial Losses and Negative Working Capital
The company reported a net loss of $(1,557,898) for 2025, an accumulated deficit of $(10,721,204), and negative working capital of $(2,144,056), indicating severe financial distress.
-
Highly Dilutive Financing Activities
In 2025, the company issued $295,000 in convertible notes for cash proceeds of $255,000, convertible at a deep discount (60-65% of the lowest traded price), and issued 2,062,500 warrants, signaling highly dilutive capital raises.
-
Increase in Derivative Liabilities
Derivative liabilities significantly increased to $1,738,804 in 2025 from $1,053,249 in 2024, representing a substantial financial obligation for the company.
Analysis · BDPT · Life Sciences
BioAdaptives, Inc.'s annual report for fiscal year 2025 highlights severe financial distress, with both management and auditors expressing substantial doubt about the company's ability to continue as a going concern. The company reported a significant net loss and a substantial accumulated deficit, alongside negative working capital. Financing activities in 2025 included the issuance of highly dilutive convertible notes at a deep discount to market price and a notable increase in derivative liabilities, indicating a desperate need for capital. Furthermore, the company operates without independent audit or compensation committees and lacks a designated financial expert on its board, exacerbating governance risks for investors in this penny stock.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 40.6% of the 330 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDPT was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $132.1K. The 52-week trading range was $0.01 to $0.13. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.